Veeva Systems Inc.

VEEV · NYSE · USD

Can new R&D software and Falcon agentic labor grow fast enough to offset a CRM business that is shrinking as a share of revenue?

Last 4 earnings calls · through Q2 FY2027

Bull case

  • Broad product growth

    Revenue is spread across R&D, quality, data and Crossix, so the commercial CRM business that built the company matters less each year.

  • Falcon agentic labor

    Selling agentic labor to the same buyers who already run Vault applications opens a budget line that does not replace software Veeva sells today.

  • Vault CRM win rate

    Veeva still wins most CRM decisions and its largest customers are migrating, which protects the installed base and the add-on sales that follow it.

  • Cash generation

    High operating margins and free cash flow fund new products and acquisitions without debt, so the growth spending comes out of current profits.

Bear case

  • Early R&D product ramp

    Development Cloud growth rests on products that are early and slow to implement, so new wins do not quickly replace the business that is maturing.

  • AI revenue timing

    Management expects AI and agentic labor to add little revenue this year, so the new business is still a promise that has to be proven with paying customers.

  • Life sciences budgets

    Veeva sells only to drugmakers and device makers, so their pricing pressure, mergers and regulatory changes reach Veeva's results without much cushion.

Bull and bear points

Growth & Execution

In short: Revenue is growing across many products, but CRM attrition and early-stage R&D products make the pace uneven.

Bull · 2

  • Total revenue grew 17.6% in the latest quarter

    Growth came from R&D, quality, Crossix and services at once, which shows the portfolio no longer depends on the commercial CRM business.

    Filed financials

  • AI moves from experiment to new business line

    A year ago AI was called a driver but not a major one; management now describes Falcon agentic labor as a new business and says customer interest is very high.

    Tone shiftQ4 FY2026 → Q2 FY2027
Bear · 2

  • Lost CRM contracts run off over several years

    Management says the departing customers cause no material harm this year or next, so the revenue they take with them fades slowly instead of all at once.

    Q3 FY2026 call

  • Development Cloud growth rests on early products

    EDC, eCOA, RTSM, safety and LIMS are large markets but still early, so R&D growth slows while revenue shifts away from eTMF and quality management.

    Q2 FY2027 call

Profitability & Financial Strength

In short: Margins and cash flow are strong, though services hiring and overlapping hosting costs pull on gross margin.

Bull · 2

  • Free cash flow reaches 47% of revenue

    Almost half of revenue becomes free cash flow, which funds product development and acquisitions without adding debt.

    Filed financials

  • Operating margin rises nearly five points

    Margin expanded even while Veeva hired in product and services, so revenue growth is outpacing cost growth rather than being bought with spending.

    Filed financials
Bear · 1

  • Gross margin slips on overlapping hosting costs

    Gross margin fell slightly as some customers run Vault CRM while still paying Salesforce royalties and cloud hosting for the old system at the same time.

    Q3 FY2026 call

Market Position

In short: Veeva leads life sciences software, though Salesforce wins some large CRM deals and regulation shapes demand.

Bull · 2

  • Vault CRM win rate stays above 80%

    Most CRM decisions outside the handful of large accounts still go to Veeva, which management cites as evidence that the losses are contained.

    Q1 FY2027 call

  • Country-by-country drug rules lock in vendors

    Safety and regulatory software must satisfy rules that differ by country and therapeutic area, so customers rarely swap a system that already works.

    Q3 FY2026 call
Bear · 2

  • Top 20 CRM expectations drift lower

    A year ago management expected about 14 of its 20 largest customers on Vault CRM; it now counts 12 committed with two decisions still open.

    Tone shiftQ4 FY2026 → Q2 FY2027

  • Drugmaker funding and pricing rules reach Veeva

    Veeva's customers depend on programs such as Medicare and on regulators such as the FDA, so cuts to either shrink the budgets that buy Veeva software.

    10-K, filed 2026-03-20